Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study
Status:
Completed
Trial end date:
2012-11-29
Target enrollment:
Participant gender:
Summary
This study is a randomised, single-blind, placebo-controlled, repeat dose study of
otelixizumab administered subcutaneously in rheumatoid arthritis patients. One cohort will
receive a single dose of adalimumab (HUMIRA, Abbott) as rescue medication to assess
additional concomitant safety and tolerability issues.